

Annual Report



**EA
TG**

European
AIDS Treatment
Group

Table of Contents

- 4 Foreword: Renewing Our Purpose, Strengthening Our Future
- 6 Executive Summary
- 8 Strategic Overview
 - 9 Mission and Values
 - 11 At a Glance: Membership
 - 13 Key Achievements
 - 14 Strategic Priorities
- 15 Community Engagement in Research
 - 16 ECAB: European Community Advisory Board
 - 18 Protocol Reviews
 - 19 Belong: Inclusion of People Living with HIV in Non-HIV Clinical Trials
- 22 European Research Projects
 - 23 READI: Research in Europe and Diversity Inclusion
 - 28 CORE: Community Response to End Inequalities
 - 32 RBDCOV: Putting Community at the Centre of Vaccine Research
 - 38 Viromarkers: Virus-related Biomarkers to Improve Management of Chronic Conditions
- 39 Quality of Life and Ageing with HIV
 - 40 The Glasgow Manifesto: A Platform for Change
- 45 Community Leadership in Prevention
 - 46 SCOPE: Amplifying Community Voices for Prevention
 - 54 DoxyPEP

Table of Contents

56 Statements, Endorsements and Sign-Ons

57 EATG Statements

58 Endorsements and Sign-Ons

60 Communications and Thought Leadership

62 Community-centred Communications

63 Campaigns

66 Publications

67 Digital Reach

68 Key Events and Engagement

70 Conferences and Events

78 Community Engagement

79 Financial Overview

80 Financial Summary

81 Funding Sources

82 Looking Ahead

83 Priorities for the Coming Year

86 Appendices

87 Glossary: Terms and Acronyms

90 Publications

90 Statements, Endorsements and Sign-Ons

91 Webinars and Events

91 Other Resources

92 Governance

Foreword



Daniela Rojas Castro

Chair of the
Board of Directors

Renewing Our Purpose, Strengthening Our Future

2025 was a demanding year for EATG, and my first year as Chair of the Board. It was a year that showed both the continued relevance of the organisation and the need to keep strengthening how we work, how we make decisions, and how we remain accountable to the communities we serve.

The context in which EATG operates is not becoming easier. Across Europe and Central Asia, progress in HIV, viral hepatitis, tuberculosis and sexual health remains uneven. Scientific advances continue, including new prevention and treatment options, but access is still shaped by inequalities, stigma, criminalisation, fragile health systems and political choices. At the same time, community organisations are working in a more difficult environment: funding is less secure, civic space is under pressure, and anti-rights movements are increasingly organised.

In this context, EATG's role remains clear. We exist to make sure that people living with and affected by HIV and related health conditions are not treated as passive recipients of policies, services or research. Community knowledge must shape decisions from the start: in clinical research, in prevention strategies, in access policies, in regulatory discussions, and in the design of health systems.

This is not only a question of inclusion. It is a question of quality, relevance and justice.

During 2025, EATG continued to bring community expertise into spaces where decisions are made. Through its projects, advocacy, partnerships, trainings and member engagement, the organisation contributed to discussions on treatment access, prevention, clinical trials, health equity, community involvement and the future of the HIV response. These contributions matter because they connect technical debates with lived realities. They remind institutions, researchers and decision-makers that policies only have value if they work for the people most affected by them.

This year also confirmed one of EATG's core strengths: its membership. EATG brings together people with different histories, countries, languages, experiences and forms of activism. This diversity is not always simple to manage, but it is one of the reasons the organisation has remained relevant for so long. A European community organisation cannot be static. It must be able to listen, renew itself, make space for new leadership, and remain open to different ways of contributing.

At the same time, 2025 was not without difficulties. Like many civil society organisations, EATG had to deal with financial pressure, high workloads, competing priorities and the need to improve internal coordination. These issues should be named with honesty. They do not diminish the work achieved during the year, but they remind us that impact depends not only on what an organisation says externally, but also on how it functions internally.

This is why the link with 2026 is important. The coming year will be a moment of renewal and consolidation for EATG. With a new strategic cycle ahead, the organisation has an opportunity to clarify its priorities, strengthen governance, improve accountability and ensure that its internal ways of working are fully aligned with its mission. For a community-led organisation, this is not an administrative detail. It is part of the politics of the organisation. The values we defend externally, participation, transparency, solidarity, equity and shared leadership, must also guide how we work together.

I want to thank EATG's members, volunteers, staff, partners and my fellow Board members for their commitment throughout 2025. Much of this work is carried out under pressure, often with limited resources, and it deserves recognition. The achievements of this year belong to all those who continued to show up, contribute, question, build and defend the relevance of community leadership.

I cannot close this foreword without dedicating a few words to Richard Stranz, who received a serious diagnosis at the beginning of the year. On behalf of the Board, I want to express our gratitude for his commitment to EATG and send him our deepest affection as he faces the journey ahead, including treatment, uncertainty and the many personal and collective challenges that come with illness. His experience reminds us of something central to our organisation: behind every role, title and responsibility, there are people, with their own health, care responsibilities, vulnerabilities and limits. A community-led organisation must never lose sight of that human dimension.

Looking ahead, EATG must remain ambitious, but also clear-eyed. The organisation has a strong history, but history alone is not enough. Its future will depend on its ability to stay politically relevant, scientifically informed, financially sustainable and genuinely community-led. That is the work ahead of us, and it is work worth doing.

Executive Summary

In 2025, EATG demonstrated what a patient-led organisation can achieve when communities are equal partners in research, policy, and care. Major projects reached their conclusion with lasting outputs.

New initiatives laid the groundwork for the years ahead. And across every area of work, EATG carried community evidence into the spaces where decisions are made.

The **RBDCOV** project concluded with the publication of the Community Engagement Toolbox, a freely available resource demonstrating what genuine community partnership in vaccine research looks like.

The **CORE** project closed after three years with results that exceeded every target: 84,700 testing opportunities across ten EU countries, 678,333 integrated screening sessions, and a contribution to the landmark approval of free PrEP in Cyprus.

Both projects leave open tools and evidence designed to outlast the funding that produced them.

EATG published clinical guidance on the inclusion of people living with HIV in non-HIV clinical trials through the Belong project and prepared it for submission to the European Medicines Agency. If adopted, this will change how eligibility criteria are set across European clinical research.

The Glasgow Manifesto under the **Ageing with HIV** project moved from a global call to action to a 7-country policy analysis, presented at AIDS Impact in Casablanca and launched at EACS 2025 in Paris, giving EATG and the iCOPE HIV coalition a concrete tool for holding national policymakers accountable.

SCOPE continued to strengthen community-led HIV prevention through a Berlin workshop, country-level partnerships in Cyprus and Armenia, and a World AIDS Day Instagram campaign that reached over 83,000 organic views.

EATG independently produced and published community-facing resources on **DoxyPEP**, filling a gap in accessible, honest prevention information.

EATG joined **READI**, a 73-partner, €66.8 million project to make clinical research more inclusive, and led a workshop to define what "community" means in a consortium of that scale.

The **European Community Advisory Board (ECAB)**, founded by EATG in 1997 and still community-led, convened meetings in Warsaw and Antwerp addressing treatment pipelines, cure research, and the global fallout from US policy shifts on HIV funding.

EATG's **communications** grew dramatically, with website traffic tripling to 38,000 monthly visitors and a SCOPE campaign going viral on Instagram. Across CROI, EACS, the European Parliament, and AIDS Impact, EATG ensured that community voices were present wherever science was discussed and policy was debated.

2025 was also the final year of **EATG's Long-Term Strategy 2020-2025**. As the organisation transitions to launch a new strategic framework, the achievements of this year, and the challenges it confronted from shrinking funding to hostile political environments, make clear both the strength of what has been built and the urgency of what comes next.

This report is a record of our strength and the urgency of the times.

It belongs to our members and staff who make it possible.

Strategic Overview



Mission and Values

EATG's mission is equitable, timely, and sustainable access to effective prevention, diagnosis, treatment, and holistic care for all people living with and affected by HIV and co-occurring conditions.

Rooted in the principles of **GIPA/MIPA** (Greater and Meaningful Involvement of People Living with HIV/AIDS), EATG values its diversity of nationalities, countries of residence, languages, sexes, genders, ages, beliefs, and ethnicities. At the foundation of all of EATG's work is a person-centred approach to addressing the needs of people living with and affected by HIV and co-morbidities.

EATG's Long-Term Strategy 2020–2025

introduced three programme areas: Quality of Life, Combination Prevention, and Partners in Science. Across all three, the cross-cutting approach is to engage, inform, and empower people living with and affected by HIV. As the 2020–2025 strategy concluded, EATG is engaging members in shaping the next long-term strategic framework.

Mission and Values

Strategic Overview



EATG members and staff at the EATG booth, hosted at the EACS 2025 Conference (Paris, October 2025)


At a Glance: Membership

In 2025, EATG's membership stood at **148**, comprising **119 ordinary members**, **28 supporting members**, and **1 honorary member**, drawn from **37 countries across the WHO Europe region and beyond**. **Eleven new members** joined during the year, from Belgium, Estonia, Greece, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

Members make EATG. They set strategic direction through the General Assembly, serve on programme committees, bodies and boards, participate in ECAB meetings and protocol reviews, and represent the community perspective in research consortia and policy spaces across Europe and Central Asia.

The **largest membership bases** are in the United Kingdom (22), Germany (9), Spain (9), Italy (7), and Ireland, Greece, and Portugal (6 each). Membership extends across Western, Central, and Eastern Europe into Central Asia, with members in Armenia, the Kyrgyz Republic, Tajikistan, Ukraine, and Uzbekistan. This geographic breadth ensures that EATG's advocacy reflects the diversity of the HIV response across the full WHO Europe region.

MEMBERSHIP BY COUNTRY



At a Glance:
Membership


Strategic Overview

Membership also reflects diversity in **HIV status** and **gender**. Of the 148 members, 91 (62%) identified as living with HIV, while 46 (31%) reported being HIV negative. By gender, the membership comprised 34 women (23%), 105 men (71%), and 7 other (6%). Among members living with HIV, men represented the largest group (72), followed by women (16).


2025 by the numbers:

- 148 members from 37 countries
- 11 new members
- 91 members living with HIV
- 78 registrations at the General Assembly (May 2025, virtual)
- ECAB meetings in Warsaw (16 members) and Antwerp (16 members)


MEMBERSHIP BY TYPE



MEMBERSHIP BY HIV STATUS



MEMBERSHIP BY GENDER



Key Achievements

In 2025, EATG closed several chapters and began several new ones. Major projects reached their conclusion, landmark outputs were published, and the groundwork was laid for the next phase of the organisation's work.

Three achievements defined the year.

First, **EATG published clinical guidance on the inclusion of people living with HIV in non-HIV clinical trials** - the culmination of the Belong project - and prepared it for submission to the European Medicines Agency. If adopted, this will change how eligibility criteria are set across European clinical research.

Second, **the CORE project concluded after three years of community-led health service delivery across ten EU countries**, producing 84.700 testing opportunities (91% above target), 678.333 integrated screening sessions, and contributing to the landmark approval of free PrEP in Cyprus. These figures represent people from marginalised communities, including migrants, sex workers, Roma communities, and men who have sex with men, who were connected to testing, prevention, and care through trusted community organisations, many for the first time.

Third, **EATG produced a 7-country policy analysis of the Glasgow Manifesto's calls to action** on ageing and HIV, developed by the International Coalition of Older People with HIV (iCOPE HIV). This moved the ageing agenda from global advocacy to country-level policy recommendations, and was presented at AIDS Impact in Casablanca and launched at EACS 2025 in Paris.

Alongside these milestones, EATG began its involvement in **READI**, one of the largest European projects on inclusive clinical research (73 partners, 18 countries, €66.8 million) and continued to convene the **European Community Advisory Board** - the community-led platform it founded in 1997 - with meetings in Warsaw and Antwerp addressing treatment pipelines, cure research, and the global fallout from US policy shifts on HIV funding. In addition, the **SCOPE** meeting in Berlin underscored community leadership in prevention, bringing activists together to shape inclusive strategies. Finally, EATG produced and published community educational materials on **DoxyPEP**, now being used and translated by local organisations across Europe.

2025 was also the final year of EATG's Long-Term Strategy 2020–2025. As the organisation prepares to launch a new strategic framework, the achievements of this year demonstrate both the strength of the current model and the urgency of what comes next. And equally impactful, new beginnings.

Strategic Priorities

2025 was shaped by three strategic priorities.

Delivering impact through concluding projects.

With CORE and RBDCOV both reaching their end, EATG focused on ensuring that their outputs - namely, the Community Engagement Toolbox, the Lessons Learnt Report, the Knowledge Hub, the psychosocial study - were published, accessible, and designed to outlast the projects themselves. The emphasis was not simply on closure but on legacy: creating resources and evidence that the wider sector can use long after the funding has ended.

Advancing policy change

The Belong guidance, the Glasgow Manifesto 7-country report, and EATG's participation in EU-level policy events (including the European Parliament, the European Health Summit, and EACS 2025) all reflected a deliberate priority to translate community evidence into regulatory and policy outcomes. EATG's role in the CORE project's multi-stakeholder meetings in Thessaloniki, Paris, and Berlin carried local evidence into European-level conversations on the sustainability of community-led health responses.

Building foundations for the future

The launch of EATG's participation in the READI project and the recruitment of a new Community Advisory Group, the preparatory work for the Long-Term Survivors Summit, and the beginning of strategic planning for the post-2025 framework all positioned EATG for what comes next.

Together, these three priorities form the bridge between the **Long-Term Strategy 2020–2025** and the new strategic framework that will begin shaping in 2026. The momentum behind the Glasgow Manifesto and the Long-Term Survivors Summit also signals **healthy ageing** and **long-term survivorship** as increasingly central to EATG's strategic direction going forward.

A year of endings led the groundwork for equally important, and equally impactful, new beginnings.

Community Engagement in Research

ECAB: European Community Advisory Board

EATG founded the **European Community Advisory Board (ECAB) in 1997** to give the HIV community **an independent, community-led voice in research and drug development**, replacing the ad hoc, industry-convened model that existed before. Nearly three decades later, EATG continues to convene and organise the ECAB, to recruit and support the pool of expert community members who participate, and to set an agenda driven by community priorities. ECAB members are treatment advocates drawn from across Europe and Central Asia, representing the full diversity of the European HIV community, who meet regularly with pharmaceutical companies, researchers, and other stakeholders to discuss scientific advancements, challenge assumptions, and advocate for treatments and prevention tools that serve everyone.

In April 2025, **EATG convened ECAB meetings with Gilead Sciences and ViiV Healthcare in Warsaw**. Sixteen EATG ECAB members participated in total. Alongside the usual discussions on new treatment safety and implementation, this meeting addressed an additional urgency: mapping the gaps left in Europe by the wave of US executive orders that had disrupted HIV funding, research, and services globally. ECAB members worked to form a clearer picture of who had been affected and how the European community could respond. The meeting also provided an update on CHANGE (Community Health & HIV Advocates Navigating Global Emergencies), an international network of over 1000 HIV advocates launched in January 2025 in direct response to the US policy shifts.



ECAB: European Community Advisory Board

Community Engagement in Research



ECAB members and partners at the ECAB meeting
(Antwerp, September 2025)

EATG convened a **second round of ECAB meetings in Antwerp in September**, again with sixteen members present, alongside Gilead Sciences and ViiV Healthcare. This round included presentations from the EU2Cure consortium and an update on the EU2Control study, both focused on HIV cure research.

What makes ECAB distinctive is not simply that EATG convenes these meetings, but that **the agenda is community-driven and community-led**. ECAB members determine the priorities. They decide which questions need asking. And they bring the perspective of lived experience into spaces where it has historically been absent or treated as secondary to the science. That principle has not changed since 1997. What has changed is the range and complexity of what ECAB addresses: from treatment pipelines to cure research, **from long-acting PrEP to the geopolitical forces reshaping the global HIV response**.

Protocol Reviews

Protocol reviews are one of EATG's longest-standing and most technically demanding contributions to the research landscape.

When EATG reviews a clinical trial protocol, **it brings community expertise to bear on the design of the study itself: who is included, how participants are informed, whether the trial's structure reflects the realities of the people it will recruit, and whether the outcomes it measures are meaningful to them.**

This work happens before a trial begins, at the point where community input can have the greatest impact on whether a study is designed inclusively. **Reviews are carried out by EATG members with scientific expertise and lived experience** and take place under confidentiality. Through the ECAB network, protocol reviews have been a core part of EATG's engagement with pharmaceutical companies and research consortia for over 25 years. The model established through ECAB has been recognised within European initiatives such as EUPATI and PARADIGM as a benchmark for meaningful patient engagement in research and development.

In 2025, protocol review discussions at ECAB meetings in Warsaw and Antwerp covered new HIV treatments from Gilead Sciences and ViiV Healthcare, as well as emerging HIV cure research through the EU2Cure consortium and the EU2Control study. Reviews extend beyond HIV treatment to cover co-infections, diagnostics, prevention technologies, and patient-reported outcomes.

Belong: Inclusion of People Living with HIV in Non-HIV Clinical Trials



Provided that effective treatment is available, HIV is generally a manageable condition that in the majority of cases no longer defines a person's overall health. Yet often with no scientific justification, people living with HIV are still routinely excluded from clinical trials for other conditions anyone may face over the course of a lifetime, such as cardiovascular disease, cancers, and diabetes, as well as hormonal conditions, such as menopause and its management. **The result is a lack of safety and efficacy data for this population, restricted access to innovative treatments, and a deepening of health inequalities that should be narrowing.**

EATG launched the Belong project in 2022 to change this. Its goal is to advocate for the adoption of clinical guidelines by European regulatory authorities that support the inclusion of people living with HIV in non-HIV clinical trials. In 2025, Belong reached a critical milestone.

Between July and October 2025, EATG developed draft clinical guidance in collaboration with a broad range of stakeholders, including people living with HIV, other patient community advocates, researchers, clinicians and industry. The guidance provides practical recommendations for defining eligibility criteria that avoid the arbitrary exclusion of people living with HIV, intended for use by trial sponsors, investigators, ethics review boards, and regulatory authorities.

Belong: Inclusion of People Living with HIV in Non-HIV Clinical Trials

On 7 October 2025, EATG convened an online consultation to review the draft. Participants emphasised that passive eligibility is not enough; **active community engagement and recruitment strategies are needed to ensure that inclusion translates into actual representation.** They supported the principle that a history of AIDS-defining illness or low CD4 counts should not automatically disqualify participants. They argued that antiretroviral therapy (ART) regimens should not be treated as barriers, and that trial teams should consider mitigation strategies rather than exclusion. And they called for HIV to be treated as one of many chronic conditions, not as a special case that justifies blanket exclusion.

The final guidance *"Clinical Trial Eligibility Criteria for People Living with HIV: Guidance on Improving Inclusion in Non-HIV Trials"* was published in late 2025. It is now intended for future discussion with regulators. You can access this guidance via the link in the appendix at the end of this report.



Memory Sachikonye, Amanita Calderon-Cifuentes and Susan Cole-Haley at the Belong symposium *"Inclusion of Women and Transgender People in Clinical Trials: Advancing Equity in Research"* (Barcelona, April 2025)

Belong: Inclusion of People Living with HIV
in Non-HIV Clinical Trials

Community Engagement in Research

The consultation brought together 23 participants, including HIV and other patient community advocates, clinicians, researchers, and representatives from the pharmaceutical industry, ensuring a broad and multi-stakeholder perspective.

Belong matters because the problem it addresses is not just historical, it is ongoing. Every clinical trial that excludes people living with HIV without scientific justification produces evidence that does not fully serve them. Every treatment approved without adequate safety data for this population is a knowledge gap that people living with HIV carry into their own healthcare decisions. We are experiencing the first generations of people living long lives with HIV. **Belong is EATG’s effort to ensure that the principle the HIV community has long championed - nothing about us, without us - applies not only to HIV research, but to all the research that affects their lives.**

European Research Projects

READI: Research in Europe and Diversity Inclusion



Everyone deserves to be represented in the research that shapes their healthcare. READI (Research in Europe and Diversity Inclusion) is a six-year, Europe-wide initiative working to make this a reality. By transforming how clinical studies are designed, conducted, and accessed, READI aims to build a more inclusive and equitable ecosystem for clinical research across Europe. Working within this project, EATG plays a crucial role in ensuring that communities actively shape this transformation, while strengthening public understanding of the value and relevance of clinical research.

Launched in January 2025, READI is one of the largest and most ambitious efforts to address the persistent underrepresentation of underserved and underrepresented (US/UR) populations in clinical studies across Europe. Funded by the Horizon Europe Innovative Health Initiative (IHI), the project currently brings together a large multidisciplinary consortium of 80 organisations from 18 countries, spanning clinical research, public health, digital health, patient advocacy, and regulatory affairs, all united by a shared goal: to build a more inclusive and equitable ecosystem for clinical research.

READI: Research in Europe and Diversity Inclusion

European Research Projects

The scale of the issue that READI seeks to address is well-documented. **While clinical studies underpin modern healthcare innovation, it often fails to reflect the diversity of populations they aim to serve.** Currently, many individuals face socio-economic, systemic, cultural and structural barriers that prevent them from participating, limiting both access to clinical research and the representativeness of its outcomes. This often results in critical knowledge gaps and produces research results that do not reflect the needs, realities and lived experiences of all healthcare users. The European population is inherently diverse; the research ecosystem must not only acknowledge this diversity but also meaningfully reflect that reality.

Within this consortium, EATG's role sits within Work Package 4 and Work Package 6, focused on **educating and informing the general public on clinical studies, as well as community engagement and connectivity.** The mandate is specific: to ensure that the perspectives of underserved and underrepresented (US/UR) populations and those facing systemic barriers are embedded in how the project communicates, engages, and ultimately delivers its outputs, not as a late-stage consultation, but rather as a core part of the research process.

Our role is not only to provide feedback, but to help define who the community is, whose voices may be missing, and what meaningful impact should look like.



Vaso Vakouftsi

Member of the
Community Advisory Group

**READI: Research in Europe
and Diversity Inclusion**

European Research Projects



READI partners and representatives
at the kick-off meeting of the project
(Madrid, January 2025)

READI: Research in Europe and Diversity Inclusion

European Research Projects

We ensure lived experiences help define what community is and guide clinical research, transforming how trials are designed.



Nuala Ryan

Member of the
Community Advisory Group

READI's first year was about building the foundations for meaningful community engagement across the life of a six-year project. **For EATG, that meant two things: assembling the right people and establishing a shared understanding of who the project is for.**

EATG attended the project **kick-off and first General Assembly in Madrid in January 2025**, where the consortium's initial 73 organisations convened in person for the first time to align priorities, establish working structures, and confirm the scope of each partner's contribution. EATG then recruited a Community Advisory Group (CAG) of six members drawn from across Europe. The CAG's role is to advise on how the project connects with, communicates to, and learns from the communities it is designed to serve, ensuring that EATG's contribution is grounded in lived experience rather than assumption.

The most substantive piece of work EATG led in 2025 **was two workshops focused on developing a working definition of 'community' within the READI project.** In a project of this scale and complexity, defining "community" is foundational: it determines who is included, whose voices are heard, and how research priorities are shaped. Without a shared, considered definition, community engagement risks becoming vague or tokenistic. EATG led this process to ensure it was neither.

READI: Research in Europe
and Diversity Inclusion

European Research Projects

READI is a six-year project, and 2025 was its first chapter; the next visible outputs will define EATG's contribution as part of the wider consortium. As EATG's involvement in Work Package 4 begins alongside EATG's continued work in Work Package 6, educational and awareness-raising materials for non-patient populations, resources for the project's digital learning platform, and the strengthening of connections between research and community networks are all already taking shape in 2026.

The research landscape is being redesigned and EATG is helping to make sure the people it affects most are shaping what comes next.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Medicines and Healthcare Products Regulatory Agency and Breakthrough T1D. This project is also supported by UKRI (UK Research and Innovation) under grant agreement No 10152425 for National Institute for Health and Care Excellence and grant agreement No 31052024 for The University Court of the University of Aberdeen

We challenged assumptions while also contributing our perspectives to how communities should be understood and represented across the whole READI project.



Daniela Rojas Castro
Member of the
Community Advisory Group

CORE: Community Response to End Inequalities

84,700 testing opportunities. Ten countries.
One proof of concept: community-led health
responses reach people that mainstream
systems miss.

**CORE was co-funded by the EU4Health
programme and led by AIDS Action Europe/
Deutsche Aidshilfe.**

A consortium of 24 organisations across 16 EU member states implemented community-based testing, linkage to care, and prevention services in ten countries: Bulgaria, Cyprus, France, Germany, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. The project set out to answer the question: can community-based organisations effectively deliver HIV, hepatitis, STI, and tuberculosis services to populations that health systems consistently fail to reach? The answer, by every measure the project tracked, was decisively: yes.



CORE: Community Response to End Inequalities

European Research Projects

EATG served as a Work Package Leader within CORE, leading on stakeholder engagement (Work Package 6) and sustainability, building the partnerships and policy dialogue needed to ensure that community-led services do not end when the funding does. Across the project's three years (January 2023 - December 2025), **EATG convened multi-stakeholder meetings across Europe, co-organised the CORE Knowledge Hub webinar series, carried the project's evidence into the European Parliament, and helped shape the concluding discussions on what must come next for community-led health responses.**


CORE partners delivered 678.333 integrated screening sessions and distributed 2,7 million condoms. They created 84.700 testing opportunities, exceeding the project's original targets by up to 91%. Positivity rates for HIV and co-infections were strikingly high for the EU context, confirming what communities already knew: people who are hardest to reach through conventional healthcare are not hard to reach at all. They are simply not being reached.

Behind the aggregate figures are specific stories of change. **In Romania**, outreach to gay men restarted in community venues where it had previously stopped. **In Slovakia**, Roma communities accessed integrated testing for the first time through peer-led services. **In Germany and Sweden**, migrant communities were connected to care through trusted community organisations. **In France**, sex workers received health services from community-led groups that mainstream providers had long overlooked.

CORE: Community Response to End Inequalities

European Research Projects

And **in Cyprus**, years of sustained community advocacy - supported by CORE and EATG's parallel SCOPE project - led to a landmark policy outcome. In October 2025, **pre-exposure prophylaxis (PrEP) became officially available and free of charge, with no restrictions linked to citizenship or health system registration.** That single change demonstrated what is possible when communities are trusted as partners in the health response.



Raminta Stuiyte moderates the CORE Multi-Stakeholders' Meeting "Resilience in Times of Uncertainty: Advancing Community-Led Health Responses through Collaboration" (Berlin, December 2025)

CORE: Community Response to End Inequalities

European Research Projects

EATG co-organised the **CORE Knowledge Hub**, a series of six webinars designed to share practical knowledge across the community sector. Co-delivered with the Correlation - European Harm Reduction Network (C-HERN), the European Sex Workers' Rights Alliance (ESWA), and the Africa Advocacy Foundation (AAF), the Hub addressed frontline priorities in the following six webinars:

- Webinar #1: The HIV, VH and STIs Testing and Diagnostics Landscape
- Webinar #2: Gender Transformative Services
- Webinar #3: Effective Engagement Strategies for Migrant Communities in HIV Testing
- Webinar #4: Using Digital Tools to Support People Who Use Drugs
- Webinar #5: Community Response on PrEP: Case Studies of Ukraine and Cyprus
- Webinar #6: How to Find Money for Your Local HIV Organisation

All sessions were recorded and remain available as an open resource; links to the webinars can be found in the appendix at the end of this report.

A key lesson from the Hub, and from CORE's broader capacity-building work, was **the need to reach frontline peer workers and community health workers directly, not only management staff**. This finding has implications well beyond CORE; it speaks to how the sector designs training and knowledge-sharing going forward.

RBDCOV: Putting Community at the Centre of Vaccine Research

What does it mean to truly involve communities in clinical research? Not as 'subjects', but as equal partners. Not as an afterthought, but as architects. Among others, the RBDCOV project set out to answer that question. In 2025, EATG helped turn that answer into something real, practical, and lasting.



The RBDCOV project, funded by the European Union's research and innovation programme, **brought together partners from five European countries - Spain, the United Kingdom, Italy, Germany, and Turkey - to test the HIPRA COVID-19 vaccine in two groups that have too often been excluded from vaccine research: adolescents and people living with immunocompromising conditions, including people living with HIV.**

Across the two trials, 240 adolescents aged 12 to 17 participated in HIPRA-HH-3, while 238 people with five different immunosuppressive conditions took part in HIPRA-HH-4. This meant 478 participants in total whose inclusion made the evidence base stronger and more representative.

From the outset, community engagement was not a box to tick. It was designed into the architecture of the project. **EATG led Work Package 9 - Community Engagement - convening and guiding the RBDCOV Community Advisory Panel (CAP):** 13 people with lived experience who shaped how the research was designed, communicated, and ultimately understood by the communities it was meant to serve.

**RBDCOV: Putting Community
at the Centre of Vaccine Research**

European Research Projects

People living with HIV have long known that being included in research is a matter of scientific integrity, equally important as fairness. Without representative participation, the evidence base is incomplete. Treatments and vaccines that work for some but not others are not good enough. RBDCOV took that principle seriously.

2025 marked the culmination of EATG's work on RBDCOV. The scale of what was produced reflects years of sustained, community-centred partnership between EATG, the CAP, and the wider consortium.

The flagship output was the **RBDCOV Community Engagement Toolbox** - a comprehensive, freely available digital resource co-developed with the CAP. Designed for activists, researchers, health professionals, and community members, it demonstrates what genuine community partnership in clinical research looks like in practice. It is built to outlast the project itself.

Two elements of the Toolbox stand out. The community-co-developed consent forms and participation sheets are available in Spanish, Catalan, English, and Turkish. They were designed to be clear and respectful and to make clear that understanding what you are agreeing to is a fundamental right, rather than a formality. Additionally, the **inclusive HIV terminology guidelines** gave researchers and communicators a practical tool for language that empowers rather than excludes. The full Toolbox spans the complete arc of the research journey, from first contact to results. It is listed in the appendix at the end of this report.

RBDCOV: Putting Community at the Centre of Vaccine Research

European Research Projects

The **ReCAP article series**, written by CAP members themselves, tackled everything from vaccine science and market regulation to youth engagement and accessibility in clinical trials. These are not summaries produced by researchers about communities. They are insights produced by communities, in their own voice, for their own audiences; a distinction which matters enormously.

We had a real seat at the table within the consortium with whom we built trust, including the pharmaceutical company developing the vaccine.



Participants at the “RBDCOV Dissemination and Community Engagement Workshop”, marking the culmination of the project's community-led approach to vaccine research (Barcelona, August 2025)

RBDCOV: Putting Community at the Centre of Vaccine Research

European Research Projects

Complementing the written series, the **RBDCOV Talks podcast** gave community advocates, researchers, and health communicators a platform to speak directly about the realities of inclusive research.

EATG coordinated a **psychosocial study** alongside the HIPRA-HH-4 trial that asked the questions clinical research rarely asks. Through surveys and in-depth interviews, 240 participants living with immunocompromising conditions, including HIV, autoimmune diseases, and kidney diseases, shared what motivated them to join, what concerns they carried, and how they felt about communication, trust, inclusion, and support through the trial process. The study is available in English, Spanish, Catalan, and Turkish. It offers practical, evidence-based insights for researchers, sponsors, ethics committees, and community organisations committed to making clinical trials more person-centred.

The CAP meant to bring in voices of the affected communities because we're not talking about HIV specifically, we were talking about being heard in a non-HIV clinical trial. So you see that was a major shift and it made our participation in the trial even more important.

RBDCOV: Putting Community at the Centre of Vaccine Research

European Research Projects

A lay language summary of the trial results, co-developed by CAP members alongside the principal investigator and HIPRA representatives, ensured that the people who participated could understand what their participation had contributed. **A comic strip** - *RBDCOV: A Vaccine Mission* - explained the trial process in plain, accessible terms, particularly aimed at young people.



RBDCOV partners and representatives at the concluding Consortium Meeting (Barcelona, August 2025)

RBDCOV: Putting Community at the Centre of Vaccine Research

European Research Projects

The project's reach was amplified through the *"It Starts and Ends with Us"* social media campaign, which reached over 432.000 individuals and generated 574.000 impressions across LinkedIn and Meta platforms. Full campaign metrics are presented in the Communications and Thought Leadership section of this report.

RBDCOV showed that **meaningful community engagement in vaccine research works. It is practical, it is achievable, and it produces better outcomes, for science and for people.**

The resources EATG helped create are open tools, freely available to any organisation working to make clinical research more inclusive. They will outlast the project that produced them. And in a landscape where community engagement is talked about far more often than it is practised, that matters.

It's a win-win for everybody.
When we community get involved
from the start, research becomes
fairer, stronger and more impactful.



Alain Volny Anne

Member of the
Community Advisory Group

Viromarkers: Virus-related Biomarkers to Improve Management of Chronic Conditions



In 2025, EATG joined the **Viromarkers** project, a major European public-private research initiative funded through the Innovative Health Initiative (IHI), bringing together leading academic institutions, industry partners and community organisations to advance virus-related biomarkers for chronic disease management. The project aims **to validate innovative biomarkers that improve the diagnosis, prognosis and monitoring of chronic viral infections, with a particular focus on HIV, hepatitis D virus (HDV) and cytomegalovirus (CMV) in immunocompromised populations**. By supporting the development of precision medicine approaches and more personalised treatment strategies, Viromarkers seeks to improve health outcomes for people living with chronic viral infections while accelerating the translation of scientific discoveries into clinical practice.

EATG plays a central role in ensuring that the perspectives of people living with HIV and other affected communities are meaningfully integrated throughout the research process. EATG contributes community expertise to key work packages **on biomarkers for susceptibility to broadly neutralising HIV antibodies, viral quantification as a diagnostic biomarker in immunocompromised populations, and dissemination, communication, exploitation and regulatory activities**. Through its participation in study protocol development, dissemination efforts and community engagement, EATG helps ensure that the project's research remains ethically grounded, patient-centred and responsive to community needs, strengthening the uptake of innovative diagnostic tools that can improve treatment decision-making and quality of care across Europe.

Quality of Life and Ageing with HIV

The Glasgow Manifesto: A Platform for Change

EATG co-created the Silver Zone - the first-ever dedicated networking zone for older people living with HIV - after six years of advocacy to have ageing recognised as a priority within the global HIV response.



Launched at the **International AIDS Conference 2022** in Montreal and returning at the 2024 conference in Munich with over **40 community-led sessions**, the Silver Zone proved both the demand and the model. It also became the launchpad for **the Glasgow Manifesto** and the International Coalition of Older People with HIV (iCOPE HIV), co-founded by EATG alongside NATAP (USA), Realize (Canada), and UTOPIA_BXL (Belgium).



The Glasgow Manifesto: A Platform for Change

Quality of Life and Ageing with HIV

Launched at the **HIV Glasgow conference in 2022**, the manifesto sets out ten calls to action for healthcare providers, researchers, community organisations, and policymakers, organised around three themes: **care, quality of life, and empowerment**.

Over 125 organisations and institutions on every continent have endorsed the Glasgow Manifesto since its launch. That groundswell of support confirmed that the calls to action resonated. **In 2025, EATG led the work to turn that momentum into policy change.**

Participants at the launch event of the report *"The Glasgow Manifesto: Advocating Policy Change for People Ageing with HIV – An Analysis of Policy Framework and Recommendations in 7 WHO Europe Countries"* join our photo campaign for the Manifesto's asks (Paris, October 2025)



The Glasgow Manifesto: A Platform for Change

Quality of Life and Ageing with HIV

In October 2025, EATG published the report *“The Glasgow Manifesto: Advocating Policy Change for People Ageing with HIV - An Analysis of Policy Framework and Recommendations - in 7 WHO Europe Countries”*. Covering Italy, Portugal, Spain, France, Romania, Turkey, and Georgia, the report analyses existing national policy frameworks against the Manifesto's calls to action and identifies where **gaps remain: in care integration, social protection, research funding, and the meaningful involvement of older people living with HIV in the decisions that affect their lives.**

EATG hosted two side events for the launch of the report. The **recommendations** were first presented in May 2025 at the **AIDS Impact conference in Casablanca**. The full report was then launched at **EACS 2025 in Paris**, bringing the findings to a wider European audience of clinicians, researchers, policymakers, and community members.



The Glasgow Manifesto: A Platform for Change

In parallel, EATG organised a series of three webinars deepening the themes of the Manifesto.

- **Empowering Ageing and Older People Living with HIV: Enduring Gaps and Emerging Opportunities (Webinar #1)** - Explored how to empower older people living with HIV through meaningful involvement in decision-making, improved research, self-management, and community support to address the unique challenges of ageing with HIV.
- **Understanding the Complexities of Women's Health (Webinar #2)** - Examined the specific health needs and lived experiences of women ageing with HIV, with a focus on menopause, gender-related health inequalities, and regional differences in care and support.
- **Psychosocial Challenges, Mental Health and Resilience in Ageing and Older People Living with HIV (Webinar #3)** - Focused on the psychosocial impact of ageing with HIV, including loneliness, stigma, mental health, cognitive health, and strategies to strengthen resilience through integrated healthcare and community support.



The Glasgow Manifesto: A Platform for Change

Quality of Life and Ageing with HIV

The Glasgow Manifesto's trajectory, from a community statement born out of the Silver Zone to a global coalition with more than 125 endorsements, to a country-level policy analysis led by EATG, demonstrates what **sustained, community-driven advocacy looks like over time**. The report is not the end of the process. It is the tool EATG will use to hold national policymakers accountable.



Community Leadership in Prevention

SCOPE: Amplifying Community Voices for Prevention

SCOPE continued to strengthen the role of communities in shaping HIV and STI prevention across Europe and beyond in 2025. As an EATG-initiated and community-led project, the foundation is to increase awareness of developments in the biomedical prevention pipeline, ensuring that this knowledge is turned into access, informed advocacy, and locally relevant action.



2025 saw the establishment of a **Community Expert Group (CEG)**. A key development for SCOPE, the CEG brings together advocates from different regional backgrounds and lived experiences to provide strategic guidance across the project. The formation of this group ensures decision-making is informed by and grounded in lived experience, and that activities and outputs reflect the needs of diverse communities. This adds strength to SCOPE's role as a platform for knowledge exchange, as well as for community-led direction and accountability. As one CEG member put it: *"SCOPE is grounded in knowing what it's like to be living with HIV, or part of a key population community."*

The impact of SCOPE's capacity-building work in 2025 combined accessible knowledge-sharing with practical application. In May, the project hosted a **community e-meeting on developments in the HIV and STI biomedical prevention pipeline**. In this session, community educators and advocates had a forum to discuss emerging prevention tools, including new PrEP options and other innovations, and to critically assess their implications for access and implementation. The session was simultaneously translated into Russian, ensuring SCOPE's contribution to sustained learning across the network by eliminating geographical blocks to attendance, with focus to the EECA region. The recording continues to be publicly available on YouTube and can be accessed via the appendix at the end of this report.

SCOPE: Amplifying Community
Voices for Prevention

Community Leadership in Prevention



Community members and partners at the
“Community in SCOPE” meeting (Berlin, July 2025)

SCOPE: Amplifying Community Voices for Prevention

Community Leadership in Prevention

Following on from this was an in-person **workshop in Berlin** in June 2025, focusing on good practices in combination prevention. The workshop emphasised peer exchange and collective problem-solving, including interactive ‘fishbowl’ sessions led by community advocates.

One of the most impactful sessions explored the relationship between pleasure, shame, and HIV. Conversations were moved beyond biomedical interventions to address the aspects of personhood often left out of formal prevention discourse. One CEG member reflected: *“So much of HIV advocacy is about battling shame. It’s hard to find pleasure when you’re battling shame.”* In these discussions, participants had space to share practical experiences across different national contexts and discuss both common challenges and effective responses. These conversations reinforced the importance of community knowledge as a driver of more effective and inclusive prevention strategies.

We are the most real people you will ever meet because we have paid with blood, sweat and tears and sperm. The price for the privilege of owning ourselves.



Amanita Calderon-Cifuentes

Member of the
Community Expert Group

SCOPE: Amplifying Community Voices for Prevention

Community Leadership in Prevention

Participant feedback from Berlin highlighted the important uniqueness of the space SCOPE had created: *“What stood out was how inclusive the environment felt. The community aspect was not just discussed in theory. It felt like we were doing what we always advocate for in this field: being heard, centering intersectionality, and truly implementing it rather than just talking about it.”*

Alongside these virtual and in-person events, **SCOPE partnered with organisations and NGOs** in several countries, to deliver outputs responding directly to each country’s needs.

The problem is not HIV but discrimination because HIV is just a virus. The virus doesn’t decide who to attack. The problems are that the politicians, the government, the institution don’t give us the tools to protect ourselves.



Marco Stizioli
Member of the
Community Expert Group

SCOPE: Amplifying Community Voices for Prevention

Community Leadership in Prevention

In Cyprus, SCOPE funded the development of a PrEP guide in four languages (Greek, English, Turkish, and French), produced in partnership with the AIDS Solidarity Movement. The guide was published in September 2025, and has been distributed through state PrEP clinics and the Cyprus PrEP Point. The initial aim of this guide was to provide clear and accessible information to those seeking prevention options. Importantly, this resource has also formed part of a wider advocacy process that contributed to the introduction of free PrEP in Cyprus in October 2025. This is an example of how SCOPE's impact extends beyond information provision to help facilitate policy changes and outcomes at a national level.

In Armenia, SCOPE supported the Right Side Human Rights Defender NGO to produce "HIV Prevention for All: A Community Guide to Health, Rights, and Inclusion." The guide was developed in Armenian and directly tailored to Armenia's needs, and it strengthens access to prevention information that is inclusive and rights-based, as well as supporting more equitable engagement with prevention services. The content was shaped with, by, and for community members and covers essential topics including condoms, PrEP, PEP, U=U, harm reduction strategies, and legal rights in healthcare settings.

Decriminalisation of sex work could decrease HIV levels globally and could be one of the most effective measures to reduce it.



Vera Rodriguez

Member of the
Community Expert Group

SCOPE: Amplifying Community Voices for Prevention

Community Leadership in Prevention

At a broader level, SCOPE monitored the implementation of combination prevention at country level via the **Combination Prevention Checklist**, a practical tool for community organisations to assess and strengthen their prevention approaches. Feedback gathered through a piloting process and consultation with the CEG is informing further iterations and improvements, ensuring that the tool remains adaptable and relevant across different contexts. A regional report will bring together self-assessments from community-based organisations in eight countries (Italy, Armenia, Sweden, Slovenia, Ireland, Croatia, Turkey and Spain) that used the updated SCOPE HIV Combination Prevention checklist to evaluate their services and national contexts for key populations. This work contributes to a more systematic and structured approach to community-led prevention and ensures the longevity of the tool and the information.

SCOPE also prioritised community voice and visibility throughout 2025. A **series of blogs** authored by community members documented key experiences and reflections from across the project. These narratives provide valuable insight into how prevention strategies are experienced in practice, complementing more formal outputs with lived perspectives.

SCOPE's influence in 2025 also extended beyond the project's own activities. Through the project, EATG strengthened ties with **regional networks** including **ESWA, TGEU, and EuroNPUD**. These partnerships increase the reach of community-led prevention work, and this is particularly important as it means EATG reaches groups that it might not reach alone. Thanks to these activities, communities that are often invisible to mainstream prevention programmes are connected to information, support, and crucial prevention response networks.

SCOPE: Amplifying Community
Voices for Prevention

Community Leadership in Prevention

A dynamic exchange of ideas during the fishbowl session at the “Community in SCOPE” meeting (Berlin, July 2025)



SCOPE: Amplifying Community
Voices for Prevention

Community Leadership in Prevention

Overall, SCOPE’s 2025 activities reflect a clear upward trajectory of progression and impact, from sharing knowledge to enabling action, to strengthening community capacity, and to supporting structural change. By combining capacity-building, resource development, and advocacy-linked outputs, the project continues to ensure that advances in HIV prevention are well-understood and translated into equitable access and meaningful impact for different communities and countries.

If you give the tools for policy changes, then real changes happen because when we are together, we are unstoppable.



Hmayak Avestisyan
Member of the
Community Expert Group

DoxyPEP

DoxyPEP (doxycycline post-exposure prophylaxis) is an emerging STI prevention strategy in which the antibiotic doxycycline is taken after sex to reduce the risk of bacterial STIs, including syphilis and chlamydia.

This prevention strategy was partly initiated by the community itself. Surveys among gay men using STI services in the UK, Belgium, the Netherlands, and Australia between 2019 and 2024 found that 8-10% of respondents were already using antibiotics as STI prophylaxis, while a 2024 community survey in Spain found that 55% of 150 gay men already using HIV PrEP had also taken DoxyPEP. Clinical guidelines are now more accurately reflecting what communities were already doing.

However, implementation varies widely across countries and regions despite clinical evidence for DoxyPEP's effectiveness being strong and growing. This is also despite CDC guidelines being published in 2024, EACS guidelines being updated in October 2025, and WHO announcing the development of formal recommendations in May 2025. Concerns about antimicrobial resistance, gaps in evidence for certain populations (particularly cisgender women), and uneven access to information made it clear that communities needed clear, reliable, and honest resources to make informed choices.

EATG saw this need and, in 2025, working independently and funded through its own resources, produced a community-informed document on DoxyPEP. This is a resource that comprehensively consists of up-to-date science, information on how DoxyPEP works, who it is recommended for, what the evidence shows, where clinical guidelines currently stand across different countries, and the questions remain open, including questions around antimicrobial resistance. The document was edited by community experts and finalised in January 2025, and was published in March 2025 in English, Polish, Slovenian, Hungarian, Greek, and Turkish. By the end of 2025, it had over 1800 views.

In June 2025, a companion outreach version was released in the same languages. The outreach flyers are a print-friendly resource designed for dissemination and health promotion by community organisations, peer workers, and health services. Both resources are published under a Creative Commons licence, and EATG has issued an open call for community organisations to produce versions in their own languages,

A link to the documents in all languages, as well the steps to adapt to local languages, can be found in the appendix.

This work reflects the principle in EATG's approach to combination prevention: that **information is itself a prevention tool**. EATG has made this information accessible, honest, community-informed, science-backed, and designed for the people who need it most.

Statements, Endorsements and Sign-ons



EATG Statements

In 2025, EATG issued a series of statements addressing major policy and public health developments affecting the global HIV response. In January, **EATG warned that the new US administration's "America First" agenda** -including the suspension of foreign aid, withdrawal from the World Health Organization, reinstatement of the Global Gag Rule, and rollback of diversity, equity and inclusion (DEI) policies- **risked undermining decades of progress in HIV prevention, treatment and human rights**, calling on European governments to help address emerging funding and service gaps. In March, EATG publicly **challenged GSK's decision to suspend diversity initiatives**, urging the company to uphold its commitments to equality and inclusive clinical research while seeking assurances that the policy would not affect clinical trials, data collection or ViiV Healthcare's operations. Later in the year, together with the **HIV Prevention Alliance**, EATG called for stronger action to achieve the goal of ending HIV as a public health threat in Europe by 2030, advocating for equitable access to comprehensive HIV prevention, person-centred models of care, meaningful community involvement, and sustained investment in prevention services.

2025 Statements

- **EATG Statement: America First, Global Health Last! What does Trump's agenda mean for global health and the HIV/AIDS response?** (January 2025) - Raised concerns about the impact of US policy changes on global health funding, HIV programmes and the rights of vulnerable populations.
- **EATG response to GSK's decision to suspend diversity work** (March 2025) - Called on GSK to reverse its decision, uphold diversity commitments, and protect inclusive clinical research and trial practices.
- **Joint Statement: HIV Prevention Alliance and EATG | United to Deliver on our SDG Commitments: Ending HIV as a Public Health Threat in Europe by 2030** (October 2025) - Urged strengthened HIV prevention policies, community-led approaches and broader access to person-centred prevention services across Europe.

Endorsements and Sign-Ons

In 2025, EATG added its voice to seven joint statements and sign-ons, on issues critical to the communities it represents. These included **calls to safeguard EU4Health funding for civil society, opposition to an EU Drug Strategy that risked undermining harm reduction and human rights, and a statement from the UNAIDS PCB NGO Delegation opposing the proposed sunseting of UNAIDS in 2026**. Support for these issues was paramount, at a moment when the global HIV response was already in crisis. Each endorsement reflected a deliberate choice to stand alongside partners in defence of the funding, institutions, and policy frameworks that community-led health responses depend on. A full list is included below, with links to each in the appendix.

Endorsements and Sign-Ons


Statements, Endorsements and Sign-ons

2025 Endorsements and Sign-Ons

- **EU4Health Civil Society Alliance - Open letter on 2025 operating grants** (April 2025) - Calling on the European Commission to publish the 2025 EU4Health operating grant call, restore operating grant support for all Framework Partnership Agreement holders, and engage with civil society on future funding cycles.
- **ESWA and Red Umbrella Sweden - Opposition to criminalisation of sex work in digital spaces** (April 2025) - Endorsed by over 90 organisations and 65+ individual experts, opposing the Swedish Government's proposal to expand criminalisation of sex work into digital spaces.
- **#SOS4EUHealthInnovation - Safeguard Our Science for European Health Innovation** (May 2025) - Joint statement with European civil society partners calling for the protection of EU-funded health research and innovation.
- **EU4Health Civil Society Alliance - Formal complaint on operating grants** (September 2025) - Urging the EU Commission to ensure immediate adoption of the 2025 EU4Health Work Plan and approve full-year funding for civil society under existing Framework Partnership Agreements.
- **UNAIDS PCB NGO Delegation - Opposition to the sunset of UNAIDS** (September 2025) - Statement opposing the proposed sunset of UNAIDS in 2026.
- **IDPC - EU Drug Strategy risks undermining harm reduction** (December 2025) - Statement on the importance of protecting harm reduction as a central pillar of drug policy, ensuring prevention and treatment reach the most marginalised.
- **EU4Health Civil Society Alliance: Health Organisations Call on EU Member States to Safeguard Support for Health and Civil Society in Europe** (December 2025) - Letter calling on EU Member States to support the reinstatement of operating grants in the 2026 EU4Health Work Programme and a strong, dedicated health budget in the next Multiannual Financial Framework (MFF) 2028-2034.

Communications and Thought Leadership

38,000 monthly website visitors, up from 12,000 the year before.



A SCOPE campaign that went viral.
And a community that voted to leave X.

In 2025, EATG's communications grew more than ever, whilst staying rooted in the voices and the causes that matter most.

Community-centred Communications

Effective communication is an expression of EATG's mission. In 2025, EATG continued to centre the voices, needs, and lived realities of people living with HIV, women, sex workers, LGBTQI+ communities, trans and gender-diverse people, and communities across the continent and beyond. This ensured that communications were **community-focused and community-led at all times**; those closest to issues, discussion points, and achievements shaped how they were communicated.

This was achieved through **community-authored blogs, campaign content led by SCOPE's Community Expert Group, and live simultaneous interpretation across a wide range of webinars**, making EATG's knowledge exchange genuinely accessible to communities across Eastern Europe and Central Asia.

EATG also adapted communications amidst the rapidly shifting global landscape. Its statement on the implications of the Trump administration's "America First" agenda for global health and the HIV response **amplified community concerns, highlighted risks to international collaboration and funding, and reinforced the case for rights-based, evidence-driven approaches to global and regional HIV policy.**

Campaigns


Two major campaigns defined EATG's communications year.

In August 2025, EATG launched the **RBDCOV campaign** *"It Starts and Ends with Us: Community at the Centre of Clinical Studies"* a social media and video campaign showcasing what meaningful community engagement in vaccine research looks like. Across a 14-day dissemination period on Meta and LinkedIn, the campaign:

- reached 432.000 people
- generated 574.000 impressions
- and achieved 110.000 completed video views (539.000 total views)

On LinkedIn alone, video content reached 1,19 million impressions and 548.000 video views. The campaign continued to gain traction through standing placements and its presence at EACS 2025 in October.

META



432.000
people reached




574.000
impressions




539.000
video views

LINKEDIN



1.190.000
impressions



548.000
video views



Shooting the video campaign *"Transform the Response: Advancing HIV Prevention through Community Leadership"* onsite at the Berlin Ballroom Pier venue (Berlin, July 2025)

Campaigns

Communications and Thought Leadership

It Starts and Ends with Us

Community at the Centre of Clinical Studies

Promotion of the video for the campaign *"It Starts and Ends with Us: Community at the Centre of Clinical Studies"*, featuring Community Advisory Panel (CAP) members sharing their perspectives on meaningful community engagement in clinical research. (Barcelona, April 2025)

Campaigns

Communications and Thought Leadership

For **World AIDS Day 2025**, EATG launched “*Transform the Response: Advancing HIV Prevention through Community Leadership*” through the SCOPE project. The campaign centred community voices in five Instagram video reels that collectively reached over 85.000 organic views and 5500 interactions, with over 70% of reach coming from non-followers. This is highly encouraging in **demonstrating the campaign’s ability to break beyond EATG’s existing audience**. The campaign contributed directly to the **32-fold increase in EATG’s organic Instagram reach in 2025**.

INSTAGRAM



5500
interactions




85.000
organic views



Shooting the video campaign “*Transform the Response: Advancing HIV Prevention through Community Leadership*” onsite at the Berlin Ballroom Pier venue (Berlin, July 2025)

Publications

EATG’s major 2025 publications, including the **Glasgow Manifesto 7-country policy report**, the **Belong clinical guidance on inclusion in non-HIV trials**, the **RBDCOV Community Engagement Toolbox**, and the **CORE Lessons Learnt Report**, are covered in their respective sections of this report. A full list of 2025 publications is included in the appendix.



Digital reach

EATG's digital footprint grew substantially in 2025, driven by strategic content development, partnerships, and platform optimisation.




Website: Approximately **38.000 individual visitors per month**. This represents a more than threefold increase from **12.000 per month in 2024**. This growth was concurrent with an expanded geographic reach; notable increases in traffic were observed from Africa and Asia, positioning EATG as one of the **leading global community-led HIV news aggregators and sources of information**.

Newsletter: Approximately **900 subscribers**, with open rates consistently between 35% and 55%.

Social media: Despite an increasingly commercialised landscape where organic reach is becoming more constrained, EATG saw consistent and at times substantial growth across platforms.

- Facebook content interactions: 2600 (2024: 970) – **a 3-fold annual increase in content interactions**
- Instagram organic reach: 211.000 (2024: 6600) – **a 32-fold annual increase in organic reach**, reflecting the significant impact of **collaborations with key community actors and consistent messaging**
- LinkedIn followers: 2111 (end of 2024: 1538) – an annual gain of **573 followers**, the highest growth rate in followers among platforms, reflecting **increasing visibility among partners and professionals**
- In January 2025, a member survey found that **82% recommended leaving X** (formerly Twitter). EATG launched a **Bluesky** account in September.

SOCIAL MEDIA



Key Events and Engagement

EATG's presence at conferences and public events ensures that community perspectives are in the room when science is presented, policy is debated, and decisions are made. EATG attended, led, and co-organised events across three continents, as well as online, over the last 12 months.

Conferences and Events

CROI 2025 - San Francisco, March

The 32nd Conference on Retroviruses and Opportunistic Infections took place in San Francisco in March 2025. Due to the US administration’s suspension of government health funding and attacks on HIV science and services, several presentations were withdrawn from the programme, and federal scientists faced travel restrictions.

At CROI, EATG had a role in co-organising the **Community Breakfast Club**, alongside the CROI Community Liaison Subcommittee and AVAC. These **daily one-hour virtual sessions** provided an informal, open space for researchers and community advocates to discuss the most significant science being presented at the conference. The Community Breakfast Club was open to anyone, including people not registered for CROI, and all sessions were recorded and shared on online platforms. Ensuring that community members could still engage with science and open discussions regardless of geography, registration, or institutional affiliation is part of EATG’s legacy at CROI 2025.

EATG co-hosted all three Breakfast Club sessions held at CROI 2025, and the links to the recordings may be found in the appendix.

Conferences and Events

Key Events and Engagement



Nataliia Gerasymchuk, EATG CORE Project Manager, presents at the “Health Equity for Marginalised Voices: EU’s Path Forward” event (Brussels, March 2025)

European Parliament - Brussels, March and December

On 5 March, EATG participated in the European Parliament policy event *“Health Equity for Marginalised Voices: EU’s Path Forward”*, co-hosted by MEPs from three political groups (S&D, Greens/EFA, and Renew Europe). The event, organised by the **Nobody Left Outside** initiative, brought together policymakers, advocates, and civil society to discuss integrating health equity into EU policies. EATG’s contribution, made within the frame of the CORE project, carried community-level evidence on health service access for marginalised populations directly into EU-level policy dialogue.

In December, EATG participated in a further European Parliament event convened by **HIV Outcomes**: *“EU Leadership at a Crossroads: Ensuring Lifespan and Gender Equity in the HIV Response”*. The event addressed the growing gap between living longer with HIV and living well, and the policy advances and action needed to close it.


Conferences
and Events

Key Events and Engagement

EATG General Assembly - May (virtual)

EATG’s annual General Assembly took place virtually on 10 and 11 May, with 78 registrations (including 5 staff). The GA is the organisation’s decision-making body, and the space in which members take stock of the previous year, review finances and governance, and set direction for the year ahead.

Members and staff participating in EATG’s 2025 Annual General Assembly, held online (May 2025)



Conferences and Events

Key Events and Engagement

AIDS Impact - Casablanca, May

EATG co-moderated a parallel session at AIDS Impact on the implementation of **Patient-Reported Outcome Measures (PROMs) in HIV care**. The session explored how PROMs can be integrated into clinical practice and research, ensuring that the lived experiences of people living with HIV are at the forefront of shaping how care is designed and delivered.

Kevin Moody, EATG Research Consultant for the PROMise project, presenting on patient-reported outcomes at the AIDS Impact 2025 Conference (Casablanca, May 2025)



Conferences and Events

Key Events and Engagement

EACS 2025 - Paris, October

The 20th European AIDS Conference, held in Paris from 15 to 18 October, was EATG's most significant conference engagement of the year. EATG contributed at multiple levels: within the main scientific programme, through curated community spaces, and via other events that extended the conference's reach to communities rarely centred in mainstream HIV discourse.

As part of the main programme, EATG hosted a dedicated session exploring **Europe's role in addressing HIV and other communicable diseases in times of permacrisis**; namely, a period defined by overlapping, ongoing global challenges. The session examined the potential impact of US funding cuts on European and global HIV responses, the effect on access to promising new prevention technologies, and what possibilities exist for Europe to at least partly compensate.

EATG curated the **Community Corner** programme within the exhibition area. This was a vibrant space for lived experience, exchange, and collaboration among community actors during conference breaks. The programme featured flash talks on topics including ageing creatively with HIV, the gendered realities of accessing PrEP, and turning personal experience into advocacy power. 'Sustain & Thrive' sessions focused on community resilience and the sustainability of community organisations in an increasingly hostile funding environment.

Conferences and Events

Key Events and Engagement

Special sessions included the presentation of **long-acting PrEP clinical trial testimonials from participants in France**; an **exhibition of children's artworks from Ukraine** titled *"Dreams of children living with HIV in Ukraine amid the war"*; and an **EATG booth** in the exhibition area, where members and staff connected with conference delegates and showcased ongoing projects.

Local community members at the EACS Community Corner present on their experiences with long-acting PrEP in the context of a clinical trial (Paris, October 2025)



Conferences
and Events

Key Events and Engagement

Two significant side events extended EATG’s EACS presence. The **STEPS 11 HIV cure workshop** - the eleventh in this community-led series dedicated to advancing community understanding of cure research - took place on 15 October during EACS. And the **CORE multi-stakeholder meeting on community-led health strategies for sex workers in France**, described in the CORE section of this report, brought together approximately 50 participants the day before the conference opened.



Moderators and speakers at the STEPS 11 workshop during the EACS 2025 Conference (Paris, October 2025)

Conferences and Events

Key Events and Engagement



Panellists at the EATG-curated special session *"HIV and other communicable diseases amid permacrisis: can Europe lead the way?"* during the EACS 2025 Conference (Paris, October 2025)

EATG also used EACS 2025 as the platform for the Paris launch of the **Glasgow Manifesto report on ageing with HIV**, covered in the Quality of Life section of this report.

European Health Summit - Brussels, December

Held on December 2 and 3, EATG's Executive Director participated in the European Health Summit, contributing to discussions on health equity, inclusive research, and the role of civil society in shaping EU health policy.

Community Engagement

Beyond conferences, EATG's 2025 calendar included community-facing activities that connected members, built capacity, and strengthened the networks that underpin the organisation's work.

The **CORE Knowledge Hub** webinars, **ECAB** meetings in Warsaw and Antwerp, the **SCOPE workshop** in Berlin, and the **CORE multi-stakeholder meetings** in Thessaloniki, Paris, and Berlin are all covered in their respective sections of this report. EATG also laid the groundwork during 2025 for the **Long-Term Survivors of HIV Summit**, taking place in Sitges, Barcelona in March 2026, in partnership with Ribbon (USA), The Reunion Project (USA), and Realize (Canada).



EATG's intervention at the CORE Local Multi-Stakeholders' Meeting "Public Health Interventions in Thessaloniki: The Role of Local Communities and Stakeholders" (Thessaloniki, September 2025)

Financial Overview



Funding Summary

EATG is committed to the transparent and accountable management of its resources. As a patient-led NGO operating across the WHO Europe region, the organisation’s finances reflect its dual identity as a community-driven advocacy organisation as well as a professional partner in EU-funded research and health programmes.

In 2025, EATG’s **total income was €1.181.178** and **total expenditure was €1.170.571**, resulting in a surplus of €10.607.

EATG’s financial statements are prepared in accordance with German law (HGB) and audited annually by an independent external auditor (Bergers Partner Steuerberater Wirtschaftsprüfer PartG mbB).

Expenditure 2025

Projects and Initiatives	€788.866
Communication and External Representation	€21.745
Learning and M&E	€5.181
Audits and compicance	€15.581
Governance	€28.363
Coordination, Oversight and Administration	€310.835
Total	€1.170.571

Funding Sources

EATG’s work in 2025 was made possible through a combination of funding streams, including:


EU funding: EATG received funding through its participation in the EU-funded research projects discussed in this report, including CORE (EU4Health), RBDCOV (Horizon 2020), READI and Viromarkers (Innovative Health Initiative),

Industry partnerships: EATG maintains transparent, values-driven partnerships with pharmaceutical companies including Gilead Sciences, ViiV Healthcare, MSD, and others. These partnerships support core activities as well as specific initiatives such as ECAB as well as various projects and are subject to EATG’s conflict of interest policy. EATG’s independence in setting priorities and agendas is non-negotiable and consistent throughout.

EATG publishes its full list of donors and partners on its website, in line with its commitment to financial transparency. A complete list is included in the appendix.

In addition, all financial compliance documents are available online, via the link in the appendix.

Income 2025



Looking Ahead

Priorities for the Coming Year

2025 demonstrated what EATG can achieve. 2026 is about ensuring that what was achieved endures, and that the organisation is ready for what comes next.

Several threads from 2025 carry directly into the year ahead.

The Belong guidance goes to the EMA. The clinical guidance on improving the inclusion of people living with HIV in non-HIV trials - developed, consulted on, and published in 2025 - is intended for formal presentation to the European Medicines Agency. This is the moment where community-led advocacy meets regulatory process. The outcome will determine whether the guidance becomes a reference point for how eligibility criteria are set across European clinical research, or whether further advocacy is needed to get it there.

READI enters its second year. EATG’s work on the READI project expands significantly in 2026, with the beginning of Work Package 4: developing educational and awareness-raising materials aimed at the general public on why participation in clinical studies matters. Alongside this, the community engagement work begun in 2025 will deepen, building on the Community Advisory Group’s expertise and the shared definition of community established through the June workshop.

Priorities for
the Coming Year

Looking Ahead

The Long-Term Survivors of HIV Summit. In March 2026, EATG - in partnership with Ribbon (USA), The Reunion Project (USA), and Realize (Canada) - brings together long-term and lifetime survivors of HIV from across Europe, North America, and beyond in Sitges, Barcelona. Through facilitated storytelling, dialogue, and skills-building workshops, the Summit will produce a Legacy Chest, a digital archive of survivors' stories. This is the next chapter of the ageing agenda that the Silver Zone and the Glasgow Manifesto began.

The Glasgow Manifesto recommendations go to national policymakers. The 7-country policy analysis published in 2025 was designed as a tool for advocacy. In 2026, EATG and iCOPE HIV will work to ensure that the recommendations reach the national policymakers in Italy, Portugal, Spain, France, Romania, Turkey, and Georgia, who are in a position to act on them.

Sustaining community-led services after CORE. CORE's concluding multi-stakeholder meeting in Berlin was clear-eyed about the sustainability challenge: funding is the single biggest threat to the services the project built, followed by a hostile ideological environment and restrictive legal frameworks. EATG will carry the evidence and lessons from CORE into its ongoing advocacy for sustained government investment in community-led health responses. Because proof of concept means nothing if the services it validated are allowed to disappear.

Priorities for
the Coming Year

Looking Ahead


A new long-term strategy. 2025 was the final year of EATG’s Long-Term Strategy 2020–2025. In 2026, the organisation will work towards a new strategic framework shaped by its members. The consultation process has already begun. The new strategy will need to respond to a changed landscape: shrinking civic space, defunding of civil society organisations, the global fallout from US policy shifts, the growing health and social complexity of ageing with HIV, and the ongoing challenge of ensuring that community voices remain at the centre of research, policy, and care.

We look forward to updating you on all these activities and achievements in next year’s annual report. Throughout the year, you can follow EATG’s work through our official media channels.

Appendices

Glossary: Terms and Acronyms


Term	Description
ART	Antiretroviral therapy. The combination of medicines used to treat HIV.
CAG	Community Advisory Group. A group of community members with lived experience who advise on a research project's direction and outputs. EATG convened a CAG for the READI project.
CAP	Community Advisory Panel. Community advisory bodies convened and guided by EATG for various projects.
CD4	A type of white blood cell targeted by HIV. CD4 counts are used to assess immune system health in people living with HIV.
CEG	Community Expert Group. The community advisory body within the SCOPE project, made up of representatives of key populations.
CHANGE	Community Health & HIV Advocates Navigating Global Emergencies. An international network of over 1,000 HIV advocates launched in January 2025 in response to US policy shifts.
Combination prevention	An approach to HIV prevention that combines biomedical tools (such as condoms, PrEP, PEP, and U=U), behavioural strategies, and structural interventions (such as addressing stigma, criminalisation, and access to services).
CORE	Community Response to End Inequalities. An EU4Health-funded project (2023–2025) delivering community-based health services across ten EU countries.
CROI	Conference on Retroviruses and Opportunistic Infections. A major annual scientific conference on HIV and related infections.
DoxyPEP	Doxycycline post-exposure prophylaxis. An emerging STI prevention strategy in which the antibiotic doxycycline is taken after sex to reduce the risk of bacterial STIs including syphilis and chlamydia.



Glossary: Terms and Acronyms

Appendices


Term	Description
EACS	European AIDS Clinical Society. EACS holds the largest European conference on HIV, held biennially.
EATG	European AIDS Treatment Group. A patient-led NGO founded in 1992, representing people living with and affected by HIV across the WHO Europe region.
ECAB	European Community Advisory Board. Founded by EATG in 1997, a community-led platform for dialogue with pharmaceutical companies and researchers on HIV treatment and prevention.
EECA	Eastern Europe and Central Asia.
EMA	European Medicines Agency. The EU regulatory authority responsible for the evaluation and supervision of medicinal products.
EU4Health	The EU's health funding programme (2021–2027).
EUPATI	European Patients' Academy on Therapeutic Innovation. A pan-European initiative providing education and training on medicines development.
GIPA/MIPA	Greater and Meaningful Involvement of People Living with HIV/AIDS. A principle affirming that people living with HIV should be meaningfully involved in decision-making processes that affect their lives.
HIV	Human Immunodeficiency Virus.
iCOPe HIV	International Coalition of Older People with HIV. A global initiative co-founded by EATG, NATAP (USA), Realize (Canada), and UTOPIA_BXL (Belgium).
IHI	Innovative Health Initiative. An EU public-private partnership funding health research and innovation.
PEP	Post-exposure prophylaxis. Medication taken after potential exposure to HIV to prevent infection.



Glossary: Terms and Acronyms

Appendices

Term	Description
PrEP	Pre-exposure prophylaxis. Medication taken before potential exposure to HIV to prevent infection.
PROMs	Patient Reported Outcome Measures. Standardised tools through which patients report directly on their own health, without interpretation by a clinician.
PROMise	EATG's project advocating for the use of PROMs in HIV care and research.
RBDCOV	An EU Horizon 2020-funded project (2021–2025) testing the HIPRA COVID-19 vaccine in adolescents and people with immunocompromising conditions, with EATG leading community engagement.
READI	Research in Europe and Diversity Inclusion. A six-year IHI-funded project (2025–2030) working to make clinical research more inclusive and representative.
SCOPE	Amplifying Community Voices for Prevention. An EATG-initiated project strengthening community capacity in HIV combination prevention.
STI	Sexually transmitted infection.
U=U	Undetectable = Untransmittable. The scientific consensus that a person living with HIV who achieves and maintains an undetectable viral load cannot transmit the virus sexually.
UNAIDS	The Joint United Nations Programme on HIV/AIDS.
WHO	World Health Organization.



Publications

- [The Glasgow Manifesto: Advocating Policy Change for People Ageing with HIV – An Analysis of Policy Framework and Recommendations in 7 WHO Europe Countries](#)
- [Clinical Trial Eligibility Criteria for People Living with HIV: Guidance on Improving Inclusion in Non-HIV Trials \(Belong\)](#)
- [RBDCOV Community Engagement Toolbox](#)
- [RBDCOV Psychosocial Study Report](#)
- [RBDCOV Lay Language Summary of Trial Results](#)
- [CORE Lessons Learned Report](#)
- [DoxyPEP Community Resources](#)
- [Community Insights on the HIV and STIs Biomedical Prevention Pipeline PrEP Implementation and Combination Prevention Advocacy Reports \(SCOPE\)](#)
- [HIV Prevention for All: A Community Guide to Health, Rights, and Inclusion \(Armenia, SCOPE\)](#)
- [Cyprus PrEP Point Leaflet \(Cyprus, SCOPE\)](#)
- [RBDCOV Talks Podcast](#)

Statements, Endorsements, and Sign-Ons

eatg.org/endorsements-and-sign-ons

eatg.org/press-releases-and-statements

Webinars and Events

eatg.org/events

Other Resources

Project Pages

[CORE](#)

[SCOPE](#)

[READI](#)

[RBDCOV](#)

[Belong](#)

[Ageing with HIV:
The Glasgow Manifesto](#)

Recordings and Multimedia

[SCOPE meeting and campaign](#)

[CORE Knowledge Hub Webinars](#)

[RBDCOV: It Starts and Ends with Us Campaign
\(Videos\)](#)

[CROI 2025 Community Breakfast Club
\(Video Session Recordings\)](#)

ReCAP Series

(All articles can be found here on the Community Engagement Toolbox,
under the heading ReCAP Articles)

[EATG Women Converse Webinars](#)

Organisational

[EATG Financial Compliance](#)

[EATG News](#)

[EATG on Social Media:](#)



Governance

Board of Directors (2025-2026)

Daniela Rojas Castro	<i>Chair</i>
Richard Stranz	<i>Secretary</i>
Willian Gomes	<i>Treasurer</i>
Nikos Dedes	<i>Vice-Chair</i>
Rosaline M’Bayo	<i>Director</i>

Internal Auditors

Tomislav Vurušić
Brian West

Ombudspersons

Karen Badalyan
Bogdan Hadarag

Development & Membership Advisory Group (DMAG)

Ann Piercy
David Haerry
Grzegorz Jezierski
Memory Sachikonye
Sanja Belak Kovačević
Aisuluu Bolotbaeva

Quality of Life Programme Chair

Mario Cascio

Combination Prevention Programme Co-Chairs

Harriet Langanke
Gus Cairns

Partners in Science Programme Chair

Brian West

Membership eatg.org/about-us/membership

Publication Credits

**Editor-in-Chief
and Creative Coordinator:**

Apostolos Kalogiannis

**Author
and Coordinator:**

Laura McAuley

Contributing Editors:

Alain Volny Anne, Amanita Calderón-Cifuentes,
Apostolos Kalogiannis, Axel Vanderperre,
Chiara Longhi, Daniela Rojas Castro,
Eleonora Tillich, Giorgio Barbareschi,
Hmayak Avetisyan, Marco Stizioli,
Marie McLeod, Nuala Ryan, Shatyam Issur,
Vaso Vakouftsi, Vera Rodriguez,
READI Communications

Design:

Synthesee

Photo credits:

Apostolos Kalogiannis, Guillén Sánchez Luján, Steven Doyle
and others





Annual Report



EATG

European
AIDS Treatment
Group

Secretariat Address:

Interoffices | Avenue des Arts 56 -4c, 1000 Brussels, Belgium

Statutory Address:

Lindemannstraße 66 40237 Düsseldorf Germany

German Charity no. VR8542 | Belgian reg. no. 0877.686.583

www.eatg.org

© 2026, EATG